Pentostatin (Nipent)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis. Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage. ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies. Exact mechanism of action in hairy cell leukemia is not fully understood.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 10/11/1991: Initial FDA approval

Also known as

  • Generic names: 2'-deoxycoformycin, dCF
  • Brand name: Nipent


  1. 1.0 1.1 Pentostatin (Nipent) package insert
  2. Pentostatin (Nipent) package insert (locally hosted backup)
  3. Nipent manufacturer's website
  4. Pentostatin (Nipent) patient drug information (Chemocare)
  5. Pentostatin (Nipent) patient drug information (UpToDate)